U.S. markets closed

Psychemedics Corporation (PMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.9700+0.3000 (+8.17%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close3.6700
Bid3.4600 x 800
Ask4.4300 x 1400
Day's Range3.6250 - 3.9700
52 Week Range3.5100 - 6.7500
Avg. Volume17,090
Market Cap22.799M
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.3300
Earnings DateNov 07, 2023 - Nov 13, 2023
Forward Dividend & Yield0.28 (7.55%)
Ex-Dividend DateMay 24, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Psychemedics Corporation
    Daily – Vickers Top Insider Picks for 09/29/2023The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    11 hours agoArgus Research
View more
  • GlobeNewswire

    Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

    ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record of leadership and a strong background in revenue growth and optimization, Shoemaker brings a wealth of experience to h

  • GlobeNewswire

    Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ACTON, Mass., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Hullinger received an inducement grant option to purchase up to 300,000 shares of common stock. The inducement awards wer

  • GlobeNewswire

    Psychemedics Corporation Reports Second Quarter 2023 Financial Results

    ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company’s revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.5 million for the quarter ended June 30, 2022, a decrease of 15%. Net loss for the quarter ended June 30, 2023, was $(726,000) or $(0.13) per diluted share, versus net loss of $(338,0